BioCentury | Nov 4, 2020
Product Development

Data Byte: BMS TYK2 inhibitor could set bar for oral efficacy in psoriasis

With Bristol Myers’ TYK2 inhibitor beating blockbuster psoriasis drug Otezla in a Phase III trial, the next question is how the oral therapy’s efficacy stacks up to that of injectable mAbs.  Bristol Myers Squibb Co....
BioCentury | Oct 16, 2020
Product Development

Recent Phase III disappointment aside, the heart failure pipeline holds plenty to look forward to

The most recent Phase III data from a heart failure candidate may have been underwhelming, but a look at the broader pipeline suggests the long period of drought in innovation could soon give way to...
BioCentury | Aug 5, 2020
Product Development

I-SPY COVID brings new set of targets to master protocols for acute respiratory distress

While most master protocols for COVID-19 have converged on an overlapping set of experimental therapies, the COVID R&D Alliance’s adaptive trial is kicking off with five therapeutic targets largely untouched in the indication. Three members...
BioCentury | May 28, 2020
Product Development

May 27 Quick Takes: EC approves Zeposia in RRMS; plus Dupixent approved in children, La Jolla, Shionogi, Alnylam and Bold

EC approves Zeposia ozanimod for relapsing-remitting MS The European Commission approved Zeposia ozanimod from Bristol Myers Squibb Co. (NYSE:BMY) to treat relapsing-remitting multiple sclerosis (RRMS). FDA approved the S1P receptor modulator in March for relapsing...
BioCentury | Apr 10, 2020
Product Development

COVID-19 roundup: New immune targets to address pandemic; plus updates from CanSino, Arcturus, Fujifilm and more

At least three new treatments for the inflammatory complications of SARS-CoV-2 infection, each with a target new to clinical COVID-19 countermeasures, have or will soon enter human studies. Movement on other fronts against the pandemic...
BioCentury | Mar 27, 2020
Product Development

March 26 Quick Takes: Pear’s digital therapeutic approved for insomnia; plus Medimetriks-Otsuka, Merck KGaA, Jazz, Roche, EpiVax

FDA approves Pear’s cognitive behavioral insomnia therapy FDA approved Somryst from Pear Therapeutics Inc. to treat chronic insomnia. The prescription digital therapeutic is the first to be approved via simultaneous review under the standard 510(k)...
BioCentury | Mar 19, 2020
Emerging Company Profile

OncoOne: targeting oxidized MIF for solid tumors

A trio of Shire veterans launched OncoOne on Wednesday with a €13 million series A round and a batch of biologics against oxidized MIF, a highly selective tumor antigen that was abandoned by the pharma...
BioCentury | Mar 13, 2020

Cratering market spoils Imara’s NASDAQ debut

Imara managed to make its public debut Thursday after raising $75.2 million in an IPO; however, the hemoglobinopathy company’s shares were immediately swept up in Thursday’s market turmoil. Imara Inc. (NASDAQ:IMRA) slipped $1 to $15...
BioCentury | Mar 10, 2020
Product Development

March 9 Quick Takes: A first for Boehringer’s Ofev; plus Cel-Sci’s COVID-19 therapy, Sinopharm, AZ, Urovant, Hengrui, Trevena, and Tetra-Shionogi

Boehringer’s Ofev approved as first therapy for lung scarring disease FDA approved Ofev nintedanib from Boehringer Ingelheim GmbH as the first therapy for chronic fibrosing interstitial lung diseases; the NDA had received Priority Review. The...
BioCentury | Feb 18, 2020

Feb. 18 Financial Quick Takes: Imara's IPO filing, Passage's terms, and fundings for OMass and Univercells

Imara listing would bring liquidity to NEA-led group Hematology company Imara Inc. filed to raise up to $86.3 million in an IPO on NASDAQ. The company's prospectus said New Enterprise Associates is its largest shareholder...
Items per page:
1 - 10 of 1107